Resona Asset Management Co. Ltd. Has $50.98 Million Stock Position in Gilead Sciences, Inc. $GILD

Resona Asset Management Co. Ltd. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 414,078 shares of the biopharmaceutical company’s stock after selling 14,834 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $50,977,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth $28,000. Financial Consulate Inc. raised its holdings in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. raised its holdings in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the period. BOCHK Asset Management Ltd acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $31,000. Finally, MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock worth $8,523,570 in the last 90 days. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 10th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Wells Fargo & Company increased their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $157.04.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $129.67 on Tuesday. The firm’s fifty day moving average price is $137.46 and its 200-day moving average price is $133.40. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market cap of $160.99 billion, a P/E ratio of 17.67 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $102.84 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.